Article
Expanding the molecular grading criteria in IDH-mutant astrocytoma.
Neuro-oncology - 1 Aug 2026
Virata Michael Christian, Samanamud Jorge, Slocum Cheyanne C, Kandoi Shrishtee, Nguyen Phuong, Savani Milan R, Shi Diana D, Sharma Sachein, Hiya Satomi, Maldonado-Díaz Carolina, Clare Kevin, Yokoda Raquel T, Vij Meenakshi, Mir Ema, Nishikawa Yurika, Umphlett Melissa, Yong Raymund L, Bederson Joshua B, Silva-Hurtado Thenzing J, Brem Steven, Hambardzumyan Dolores, Snuderl Matija, Viapiano Mariano S, Abdullah Kalil G, McBrayer Samuel K, Hatanpaa Kimmo J, Walker Jamie M, Tsankova Nadejda M, Richardson Timothy E
Abstract excerpt
BACKGROUND: IDH-mutant astrocytomas are classified as WHO grade 4 in the presence of conventional high-grade histologic features and/or homozygous CDKN2A/B deletion in the 5th edition of the WHO Classification of Central Nervous System Tumour guidelines. However, work over the past decade has indicated a number of other molecular alterations that warrant consideration as potential prognostic markers. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
